Pituitary adenoma

Jump to navigation Jump to search

For patient information click here

Pituitary adenoma
ICD-10 D35.2
ICD-9 237.0
ICD-O: Template:ICDO
MeSH D010911

Pituitary adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pituitary adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural history, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pituitary adenoma On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pituitary adenoma

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pituitary adenoma

CDC on Pituitary adenoma

Pituitary adenoma in the news

Blogs on Pituitary adenoma

Directions to Hospitals Treating Pituitary adenoma

Risk calculators and risk factors for Pituitary adenoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Classification

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

MRI

CT

Treatment

Treatment options depend on the type of tumor and on its size:

  • Prolactinomas are most often treated with bromocriptine or more recently, cabergoline which, unlike bromocriptine, decreases tumor size as well as alleviates symptoms, both dopamine agonists, and followed by serial imaging to detect any increase in size. Treatment where the tumor is large can be with radiation therapy or surgery, and patients generally respond well. Efforts have been made to use a progesterone antagonist for the treatment of prolactinomas, but so far have not proved successful.
  • Thyrotrophic adenomas respond to octreotide, a long-acting somatostatin analog, in many but not all cases according to a review of the medical literature. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment.Template:Ref label

References

  1. ^ Template:Note label Chanson, Philippe; Weintraub, Bruce D.; and Harris, Alan G. (1993) Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomata. Annals of Internal Medicine 119 (3), 236-240.

See Also

External links

cs:Adenom hypofýzy nl:Hypofysetumor sk:Adenóm hypofýzy sv:Hypofystumör

Template:WikiDoc Sources